{"id":{"repo_id":"buffalo","oai_identifier":"oai:ubir.buffalo.edu:10477/78518"},"canonical_url":"https://search.dev.ndltd.org/etd/buffalo/oai:ubir.buffalo.edu:10477/78518","repository":{"repo_id":"buffalo","name":"Buffalo","base_url":"https://ubir.buffalo.edu/oai/request"},"display":{"title":"The Effect of Insuline Like Growth Factor-II and Chromeceptin on Osteoblast Cells","abstract":"M.S.","abstract_html":"M.S.","abstract_has_math":false,"creators":["Nourah, Dalia"],"institution":"State University of New York at Buffalo","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Dziak, Rosemary","Oral Biology"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-10-26T02:54:42Z","date_published":"2018-10-26T02:54:42Z","updated_at":"2026-07-27T19:05:12Z","subjects":["biology"],"languages":["eng"],"rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10477/78518","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dziak, Rosemary","Oral Biology"]},{"key":"dc:creator","label":"Author","values":["Nourah, Dalia"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-10-26T02:54:42Z","2018","2018-07-18 12:23:33"]},{"key":"dc:publisher","label":"Institution","values":["State University of New York at Buffalo"]},{"key":"dc:type","label":"Dc Type","values":["Text","Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["biology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/10477/78518"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["M.S.","IntroductionThe insulin-like growth factors (IGFs) are the most abundant growth factors stored in bone andproduced by osteoblasts. They have an important role in regulating osteoblast function and bonedevelopment and maintenance. IGFs can act in an endocrine, paracrine or autocrine manner andare regulated by a family of six IGF binding proteins (IGFBPs). IGF-II is the predominantcirculating IGF in adults and considered as potent mitogen whose deregulation is linked todiverse pathologies and plays a role in tumorigenesis, development of different types of cancerssuch as liver, breast and prostate cancers, metastasis and resistance to existing forms of cancertherapy. Chromeceptin is a synthetic small molecule that induces expression of IGF inhibitorygenes. Research has shown that chromeceptin inhibits insulin-induced adipogenesis anddecreases the growth and viability of hepatocellular carcinoma cells that overexpress IGF-II. Aprevious study conducted in our lab showed the effect of chromeceptin as an inhibitor forosteosarcoma cells. However, studies on the effect of exogenous IGF-II and chromeceptin onnormal bone cells were lacking, but needed to help in the understating of possible therapeutic useof the agent for osteosarcomas.The aim of the study: to study the effect of exogenous and endogenous IGF-II on humanosteoblasts activity and differentiation as well as the effect of chromeceptin on these parameters.Materials & Methods:Primary human calvarial osteoblastic cells purchased from a commercial supplier were used inthese studies. The MTT assay was used to assess osteoblast cells growth activity after incubationwith different concentration of IGF-II and chromeceptin. Enzyme-linked immunosorbent assays(ELISA) were used to detect the endogenous levels of IGF-II when chromeceptin was added atdifferent concentrations. Alkaline phosphatase assay was used to assess the osteoblastdifferentiation capability after adding IGF-II and chromeceptin.Results:The experiments showed that adding exogenous IGF-II at different concentrations incubated for24 hrs had no significant effect on osteoblast activity measured by MTT. On other hand, whenthe cells were incubated with IGF-II at a concentration of 100ng/ml for 48 hours, there was aslight decrease in cell activity but not this effect was not statistically significant. Chromeceptineffects on endogenous levels of IGF-II produced by osteoblasts showed significant inhibitionwith different concentrations with the concentration of 0.3 μM producing the most inhibitoryeffect. Moreover, the studies of IGF-II on osteoblast differentiation measured by alkalinephosphatase assay revealed no significant effect. Addition of chromeceptin at concentrations (0.3μM, 3μM) produced decreases in alkaline phosphatase activity that was not statisticallysignificant.Conclusion:This study contributes to the clarification of the effect of IGF-II and chromeceptin on normal bonecells in order to differentiate between the osteoblasts and osteosarcomas cells (G292) in aprevious study. The findings indicate that there is no difference in the reaction of normalosteoblastic cells and osteosarcomas cells after application of both treatments. The IGF-II had nosignificant effect on differentiation and proliferation of the cells while chromeceptin has aninhibitory effect on both. Further research is needed to differentiate between different types ofsarcomal cells as well as explaining the difference between normal cells and osteosarcomas cellsin other aspects."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["The Effect of Insuline Like Growth Factor-II and Chromeceptin on Osteoblast Cells"]}]}],"canonical_facts":{"dc:contributor":["Dziak, Rosemary","Oral Biology"],"dc:creator":["Nourah, Dalia"],"dc:date":["2018-10-26T02:54:42Z","2018","2018-07-18 12:23:33"],"dc:description":["M.S.","IntroductionThe insulin-like growth factors (IGFs) are the most abundant growth factors stored in bone andproduced by osteoblasts. They have an important role in regulating osteoblast function and bonedevelopment and maintenance. IGFs can act in an endocrine, paracrine or autocrine manner andare regulated by a family of six IGF binding proteins (IGFBPs). IGF-II is the predominantcirculating IGF in adults and considered as potent mitogen whose deregulation is linked todiverse pathologies and plays a role in tumorigenesis, development of different types of cancerssuch as liver, breast and prostate cancers, metastasis and resistance to existing forms of cancertherapy. Chromeceptin is a synthetic small molecule that induces expression of IGF inhibitorygenes. Research has shown that chromeceptin inhibits insulin-induced adipogenesis anddecreases the growth and viability of hepatocellular carcinoma cells that overexpress IGF-II. Aprevious study conducted in our lab showed the effect of chromeceptin as an inhibitor forosteosarcoma cells. However, studies on the effect of exogenous IGF-II and chromeceptin onnormal bone cells were lacking, but needed to help in the understating of possible therapeutic useof the agent for osteosarcomas.The aim of the study: to study the effect of exogenous and endogenous IGF-II on humanosteoblasts activity and differentiation as well as the effect of chromeceptin on these parameters.Materials & Methods:Primary human calvarial osteoblastic cells purchased from a commercial supplier were used inthese studies. The MTT assay was used to assess osteoblast cells growth activity after incubationwith different concentration of IGF-II and chromeceptin. Enzyme-linked immunosorbent assays(ELISA) were used to detect the endogenous levels of IGF-II when chromeceptin was added atdifferent concentrations. Alkaline phosphatase assay was used to assess the osteoblastdifferentiation capability after adding IGF-II and chromeceptin.Results:The experiments showed that adding exogenous IGF-II at different concentrations incubated for24 hrs had no significant effect on osteoblast activity measured by MTT. On other hand, whenthe cells were incubated with IGF-II at a concentration of 100ng/ml for 48 hours, there was aslight decrease in cell activity but not this effect was not statistically significant. Chromeceptineffects on endogenous levels of IGF-II produced by osteoblasts showed significant inhibitionwith different concentrations with the concentration of 0.3 μM producing the most inhibitoryeffect. Moreover, the studies of IGF-II on osteoblast differentiation measured by alkalinephosphatase assay revealed no significant effect. Addition of chromeceptin at concentrations (0.3μM, 3μM) produced decreases in alkaline phosphatase activity that was not statisticallysignificant.Conclusion:This study contributes to the clarification of the effect of IGF-II and chromeceptin on normal bonecells in order to differentiate between the osteoblasts and osteosarcomas cells (G292) in aprevious study. The findings indicate that there is no difference in the reaction of normalosteoblastic cells and osteosarcomas cells after application of both treatments. The IGF-II had nosignificant effect on differentiation and proliferation of the cells while chromeceptin has aninhibitory effect on both. Further research is needed to differentiate between different types ofsarcomal cells as well as explaining the difference between normal cells and osteosarcomas cellsin other aspects."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/10477/78518"],"dc:language":["eng"],"dc:publisher":["State University of New York at Buffalo"],"dc:rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"dc:subject":["biology"],"dc:title":["The Effect of Insuline Like Growth Factor-II and Chromeceptin on Osteoblast Cells"],"dc:type":["Text","Thesis"]},"updated_at":"2026-07-27T19:05:12Z"}